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Introduction
   Now small RNAs that are transcribed from genomic 
DNA are commanding considerable attention. 
With the emergence of the high-throughput next-
generation sequencer (NGS)[NOTE 1], there has been 
an advancement in large-scale transcription analysis 
(transcriptome), which symbolizes progress in the 
post genomic era. Consequently, this reveals the great 
number of RNAs were transcribed from non-protein-
coding DNA regions (non-coding RNA: ncRNA) 
in human genome. It was also revealed that protein-
coding DNA sequences account for only 2% of human 
genome, with the remaining 98% is represented in 
non-coding DNA. In addition, it gradually became 
clear that ncRNA, formerly believed to have no 
physiological activity, was equipped with important 
functions, such as transcription regulation. 
   The length of ncRNA transcribed from genomic 
DNA varies from 20 bases to more than 200 bases 
in length. Among these, microRNA (miRNA), 
which constitutes group of small ncRNA generally 
18-25 bases in length, is receiving a considerable 
attention[1]. miRNA belongs to a member of the small 
1
RNA molecular family (Figure 1), and negatively 
regulates gene expression (gene silencing)[2], an RNA 
interfering (RNAi) molecule. While a well-known 
RNAi molecule, small interfering RNA (siRNA), is 
a small RNA that is artificially synthesized, miRNA 
exists endogenously in the cell. This means that there 
is an innate gene-silencing mechanism in our bodies. 
Ever since this was confirmed, miRNA research has 
been advancing drastically.
   Here, I report the research trends, with a focus on 
the clinical application of miRNA, a new category of 
RNA. 
Biological property and function of 
miRNA
 2-1 Discovery of miRNA
     The first miRNA was discovered in 1993. At this 
point the concept of miRNA did not exist. Lee et al 
from Harvard University (at the time) captured a small 
RNA that bound to messenger RNA (mRNA) coding 
a certain protein-coding gene in C. elegans[3]. This 
phenomenon, however, was believed to be specific to 
C. elegans, and together with the immature extraction 
technique of small RNA at the time, there was no 
subsequent progress in the project. On the other hand, 
Fire from the Carnegie Institute for Science and Mello 
et al from the University of Massachusetts discovered 
that transcription inhibition occurred on the same gene 
that was responsible for the phenomenon found by 
Lee et al when they injected a small double stranded 
RNA (siRNA) that constructed to bind to a part of the 
mRNA sequence in C. elegans. Both teams reported 
the results in 1998[4], making this the first report on 
RNAi. 
[NOTE 1]  Next-generation high-speed sequencer: Genetic analysis equipment, introduced around 2006, that can 
do the exhaustive analysis. The term “next-generation” was originally applied during its development. 
The third generation, which is currently under development, is called the “next next-generation,” and 
has a sequencing ability that is 300–1000 times that of the first generation. 
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   This discovery turned over all the classic central 
dogma[NOTE 2], and RNAi technology, now a daily 
experimental tool, was diffused immediately in 
the wold. Now RNAi has become widely used as a 
standard experimental tool for molecular biology. It is 
also applied for medical research, whereby the concept 
of siRNA drug innovation targeting to suppress the 
expression of disease-related genes was developed, 
and animal research started within a few years of the 
first discovery[7]. Drug innovation venture companies 
specializing in siRNA drugs were founded one after 
another. Some siRNA drugs have already advanced 
into Phase III clinical trial. In 2006, Fire and Mello 
were both awarded the Nobel Prize.
   miRNA started to gain attention several years after 
siRNA, when small RNA discovered by Lee et al was 
found to be preserved in several species, including 
mammals[5]. In other words, there was a possibility that 
mRNA is regulated post-transcriptionally by miRNA, 
and this possibility attracted great interest. This was 
confirmed immediately using C. elegans[6-8]. The term 
“micro RNA” came around this time. Subsequently, 
locked nucleic acid (LNA) technique which has high 
affinity for complimentary DNA sequence was applied 
to ncRNA research, enabling the detection of a small 
amount of nucleic acid. This novel technique enabled 
the gene expression analysis of small RNA, and pushed 
forward the miRNA research.
   This is evidenced in the change in the number of 
research articles. The number of articles detected 
by a single-word search with “miRNA” has been 
increasing since 2002, and the increase has been 
especially rapid in the recent few years. The number is 
reaching to that of RNAi as a whole in 2010 (Figure 2). 
Recently, miRNA function is also studied in the field 
of higher brain function research, such as learning and 
memory[9]. The most widely expanding, however, is 
the disease-related miRNA research based on miRNA 
expression analysis, probably due to the fact that 
generalized functional mechanisms were discovered 
for all miRNA. 
   One can take the initiative in drug development by 
discovering how each miRNA regulates the expression 
of important genes. Massive money has been already 
invested for nucleic acid development targeting 
miRNA in Europe and the United States.
[NOTE 2]  Central Dogma: A general molecular biological doctrine of genetic information flow where genetic 
information in the DNA is transferred and expressed in protein via RNAs. It was proposed by F. 
Crick in 1958. However, the doctrine has since been adjusted from the original due to the discovery 
of such phenomena as reverse transcription and splicing.
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Figure 2 Annual increase of miRNA-related articles published (Search 
data on PubMed)
Search key word was either “microRNA” or “RNAinterference”.
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Figure 2 : Annual increase of miRNA-related articles published (Search data on 
PubMed)
Search key word was either “microRNA” or “RNAinterference”.
Prepared by the STFC
24
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
2-2 Sequence length of miRNA
   miRNAs are single strand RNAs with 18–25 
nucleotides, and widely exist in viruses, plants and 
animals. The most unique property of miRNA is that 
its own sequence is integrated in the DNA sequence. 
The miRNA sequences are usually within the 
regions[10]. Recently, miRNA had also been found in 
exons. This property provides a medical advantage 
over the exogenous siRNA. For example, siRNA can 
elicit an immunological response (side effect) similar 
to the one against RNA virus. On the other hand, 
since miRNA is a nucleic acid molecule that already 
exists inside the cells, it is unlikely to trigger an 
explicit reaction. This is an extremely useful property 
for drug development.
2-3 miRNA Synthesis
    The synthetic pathway of miRNAs on the DNA 
is shown in Figure 3. Hundreds to thousands of 
base-long primary miRNA (pri-miRNA) including 
miRNA sequence are generated by specific enzyme 
(RNA polymerase II) from long single-stranded RNA 
transcribed from DNA in the nucleus. Multiple stem-
loop structures develop in a sequence-based manner 
on pri-miRNA, and another enzyme (Drosha) cleaves 
its root, producing small hairpin-like single-stranded 
RNA. This is the precursor (pre-miRNA) to miRNA, 
and is transported into the cytoplasm from the nucleus 
by Exportin-5, a nuclear export protein. Although 
discussion about the maturation of pre-miRNAs into 
single stranded miRNAs is still ongoing, it is generally 
believed that a pre-miRNA is spliced on both sides by 
a complex made of the enzyme called “Dicer” and a 
cofactor “TRBP” to arrange double-stranded miRNA 
of about 22 bases. Very recently, a miRNA that did 
not rely on Dicer splicing was discovered[11]. The 
double strands miRNA separate later, with one, guide 
strand, selectively remaining to mature and another 
one, passenger strand, breaking down. Complete 
miRNA is taken in by a complex made of ribonucleic 
acid RISC (RNA-induced silencing complex) and 
Argonaute protein, and turned into a functional 
miRNA-RISC complex (miRICS) (Figure 3).
2-4 Function of miRNA
   The function of miRNA is to negatively control 
gene expression (Figure 4). In general, miRNAs 
suppress mRNA translation at the posttranscriptional 
level. In plants and C. elegans, it has been reported to 
suppress the transcription itself from the DNA[12,13]. 
This suppression is not a complete shut out, but rather 
miRNAs are now revealed to act like a fine tuner by 
modulating the rate of mRNA. 
   There are still a few different hypotheses on the 
mechanism of miRNA’s action, however, in general, 
miRISC with miRNA moves toward the target mRNA, 
and binds miRNA in the complementary region in the 
3’ untranslated region (3’ UTR) to either terminate the 
translation or to lead to degradation of the mRNA to 
interfere with the gene expression[14, 15]. When miRNA 
is bound to the completely complementary region of 
mRNA, like siRNA, mRNA gets degraded. What is 
interesting is that for miRNA, the sequence does not 
have to be a perfect match with the target-binding 
region. In this case, the strength of the inhibition 
varies depending on the sequence. However, the 
【図表3】
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7-base sequence between 2nd and 8th nucleotide from 
the 5’ end is called “seed region,” and a complete 
match of the sequence is required. Therefore, miRNA 
does not function one-to-one relationship like siRNA, 
but rather one-to-multiple. This property is extremely 
important when finely tuning the gene expression. 
However, how it is done at good balance remains 
to be revealed. In addition, one miRNA targets 200 
mRNAs on average[16]. In other words, one mRNA 
regulated by multiple miRNAs. This means that 
1/3–1/2 of the genes coding proteins come under the 
control of miRNA after their transcription.
   There are 16,772 miRNAs registered on the website 
miRBase (as of May 2011). Among them, human 
miRNAs number up to 1424; and though it was once 
predicted that there were only about 900 human 
miRNAs, the number is currently at 2000. 
miRNA and Diseases
   Since the RNA programs, including RNA silencing, 
are closely involved in homeostatic maintenance, 
their disruption lead to potentially life-threatening 
situations. In terms of the relationship between 
miRNA and diseases, the field of cancer research is 
the most advanced. When the biological property of 
miRNA was revealed, many researchers predicted 
the implication of miRNA in cancer development. 
In 2006, Croce et al from Ohio State University 
conducted miRNA expression analysis in various 
types of cancer. They found expression profiles that 
differed from the ones in the normal specimen in all 
analyzed cancers (breast cancer, lung cancer, stomach 
cancer, colon cancer, pancreatic cancer and prostate 
cancer[17]). Table 1 shows the list of miRNA that 
changes expression in major cancers. The expression 
of miR-21 is increased in all cancers listed here. 
Subsequently, the increase of miR-21 expression was 
found in papillary thyroid cancer and acute myelocytic 
leukemia as well. Therefore, it is speculated that miR-
21 is strongly involved in cancer onset, and in fact, 
multiple transcriptional repressors including NFIB 
are now found to be the target genes of miR-21[18]. 
The increase of miR-21 is believed to inactivate these 
transcription factors, which consequently weakens the 
tumor suppressive activity. In addition, the expressions 
of mir-191 and mir-221 are now found to be increased 
in many cancers. 
   On the other hand, there are miRNAs whose 
expression decreases in cancer (Table 1). The 
expression of the let-7 miRNA, found to be involved 
in cell proliferation in C. elegans, is decreased in 
human cancer cells including breast cancer, lung 
cancer and stomach cancer. The target genes of this 
miRNA include so-called oncogenes such as Ras 
and HMGA2[19-21], suggesting the possibility that the 
decrease of let-7 expression  activates these oncogenes. 
The strong involvement of let-7 in cancer can be 
found clinically as well. The cases of lung cancer in 
which the let-7 expression decreased do not indicate 
favorable prognosis.[22]
   There are miRNAs which show changes of 
expression levels in specific types of cancer (Table 
1). Although a detailed relationship with their target 
Figure 4 : Active Sites of miRNAs
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Figure 5 : Proportion of Diseases Targeted for Nucleic Acid Drug Development
genes remains unknown in most cases, there are cases 
like miR-19, which has been identified as suppressor 
of apoptosis of lymphocytes, thereby turning them 
cancerous[23]. These miRNAs are expected to be 
useful as specific biomarkers for individual cancer 
(discussed later). 
   For diseases other than cancer, miR-29 is found to 
be involved in cardiac fibrosis, whereas among viral 
infectious diseases, miR-122 is found to be involved 
in the replication of hepatitis C virus. One interesting 
example is that human cytomegalovirus has miRNA 
sequences encoded within its viral genomic DNA, 
enabling it to pass through the human immunological 
system[24]. In metabolic diseases, miR-375 is identified 
to be involved in insulin secretion and miR-146 in 
the pathology of arthroreumatism. In Alzheimer’s 
disease, miR-101 and miR-29 clusters were discovered 
to be involved in amyloid β formation, the cause of the 
disease, and now research on it is being extensively 
conducted.
Types of Cancer Elevated Expression (onco-miR) Reduced Expression (suppression-miR)
Cererbral cancer miR-21, 221 miR-128,181
Breast cancer Mir-9-1, 10b, 17-5p21, 21, 29b-2, 34, 146, 555, 
181b-2, 213
lit-7, miR-9, 26a-1-p, 27b, 29b-2, 32, 33, 30a-
5p, 95, 101-1, 124, 124a-3, 125a, 125a-p, 
126, 140, 143, 145, 181c-p, 198, 192-p, 199b-
p, 216-p, 218-2, 219-1, 220, 224
Lung cancer miR-17-5p, 17-92, 21, 24-2, 106a, 128b, 146, 
150, 155, 191, 192, 197, 199a-1, 203, 205, 210, 
212, 214
miR-203, 205
Esophageal cancer miR-21, 93 let-7
Gastric cancer miR-21, 24-1, 24-2, 29b-2, 30c, 31, 32, 96, 106a, 
107, 128b, 135b, 155, 183, 191, 221, 223
let-7, miR-34, 127, 133b, 143, 145
Colorectal cancer miR-17-5p, 20a, 21, 24-1, 24-2, 29b-2, 30c, 31, 
32, 96, 106a, 107, 128b, 135b, 155, 183, 191, 
221, 223
let-7, miR-34, 127, 133b, 143, 145
Hepatic cancer miR-15b, 18a, 21, 106b, 221, 222, 224 let-7, mir-101, 122a, 125a, 195, 199a, 200a
Pancreatic cancer miR-17-5p, 20a, 21, 24-1, 24-2, 25, 29b-2, 30c, 
32, 92-2, 100, 106a, 1-7, 125b, 128b, 146, 155, 
181a, 181b-1, 191, 196a, 196b, 199a-1, 212, 214, 
221, 223, 301, 376a
miR-139, 142-p, 345,375
Prostate cancer miR-17-5p, 20a, 21, 25, 30c, 32, 92-2106a, 146, 
181b-1, 191, 199a-1, 214, 223
miR-15a, 16, 143, 145, 218-2
Uterus cancer miR-21, 199a miR-143, 145
Table 1 : miRNAs with Cancer-specific Expressional Alteration
Prepared by the STFC
[NOTE]  miRNAs are numbered according to the order of discovery. “Let” was discovered in C. elegans in the 
early stages. 
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   These disease-specific miRNAs are the targets of 
nucleic acid drug development. Figure 5 shows the 
proportion of the target diseases of the whole nucleic 
acid drugs including siRNA at the moment, but the 
proportion would be similar even if it were specific 
to miRNAs. In each disease, however, the very basic 
question as to whether the increase or decrease of 
miRNA expressions actually cause the disease or if 
they are a consequence of the disease is not yet clear. 
While research for clinical application progresses, 
basic research is also being conducted simultaneously. 
Since the identification of disease-specific miRNAs 
that cause the onset or exacerbation will lead to 
intellectual property as well as drug development, 
great efforts are made to research and develop them 
worldwide. 
Trends of miRNA Research Aimed 
for Clinical Application
 4-1 Development of drugs targeting miRNA
    There are two main strategies for developing drugs 
targeting miRNA: (1) by suppressing the disease-
specific miRNAs whose expression are increased in 
diseases and (2) by supplementing miRNA whose 
expression decreased.
   For (1), siRNA for miRNA maybe evoked, but it is 
mostly impossible due to the short length of miRNA 
sequence. Therefore, development is generally done 
with agonistic nucleic acid molecules at this point. 
The most advanced in nucleic acid drugs using this 
method is the drug for chronic hepatitis C developed 
by Santaris Pharma based in Denmark, and is already 
in Phase II of the clinical trials. Hepatitis C virus 
(HCV) is known to use the host’s miR-122 when 
replicating itself. Therefore, Santaris Pharma designed 
an agonistic nucleic molecule for miR-122, and aimed 
to block HCV multiplication by suppressing miR-122 
action. Last year, results of a preclinical study using 
primates were reported in Science[25]. The number of 
virus in the blood decreased and the hepatic function 
recovered without noticeable side effects. In the near 
future, the first nucleic acid drug targeting miRNA is 
likely to come out. 
   Alnylam and ISIS with reputable technique to 
synthesize nucleic acid molecules founded a merged 
company, Regulus Therapeutics (California, US) 
specifically for miRNA drugs, and started the 
development of HCV drugs targeting miR-122. They 
are scheduled to start clinical studies in 2012. 
   Many other pharmaceutical companies are also 
conducting research and development of nucleic acid 
drugs (Table 2), and are expected to proceed to clinical 
trials in the near future.
   On the other hand, the method to supplement 
miRNAs in (2) is to recover miRNAs by injecting 
synthetic miRNAs. The technique of siRNA drugs 
can be applied for this type of nucleic acid drugs. 
Ochiya and his colleagues from National Cancer 
Center identified 9 miRNAs whose expression was 
decreased in the prostate cancer cell lines. Among 
them, they focused on miR-16 which seemed most 
involved in malignant alteration of the cancer. miR-16 
is a miRNA involved in the regulation of cell cycles. 
When the researchers conducted an experiment 
to induce miR-16 with the mouse model of bone 
metastasis of prostate cancer, the metastasis to the 
bones was suppressed significantly after injection in 
the mice without side effects (Figure 6)[26]. This means 
that the recovery of miR-16 triggered apoptosis in the 
cancer cells. As seen here, for the downregulation of 
the miRNA expression in a disease, a certain amount 
of effectiveness can be achieved by putting it back to 
the body. A lung cancer drug with let-7 (Mirna) and a 
hepatic cancer drug with miR-24 (Regulus) are under 
development (Table 2). 
   The development of a drug delivery system (DDS) 
to transfer the drug to the target organ will be an 
important key for the development of nucleic acid 
drugs such as miRNA and siRNA. At present, direct 
injection to the affected area is the main method. 
However, intravenous injection or oral administration 
is favorable. As for DDS, various ways had been 
studied since the antisense DNA research had been the 
mainstream. However, solid DDS technology has yet 
to be established. For miR-16 induction in Figure 6, the 
biomacromolecule known as atelocollagen was used 
for DDS. Atelocollagen was developed for artificial 
organs, and the FDA certified it as the molecule with 
the best biocompatibility. Ochiya et al injected the 
complex of miR-16 and atelocollagen from the tail 
vain for systemic delivery, and that was effective at 
least in mice. Although there are many more hurdles 
for DDS, atelocollagen has great potential for clinical 
use for humans. 
4
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4-2 Application of miRNAs as biomarkers 
   The usefulness of miRNA, that siRNA does not 
have, is its application for biomarker development. 
There is hope for the development of disease 
biomarkers for diagnosis as well as screening. 
In particular, there is a great necessity for cancer 
detection. In recent years, there has been a widely 
conducted search for biomarker molecules based on 
proteome analysis, but they have yet to be discovered. 
   The expression profile of miRNA differs largely 
depending on the organ as well as healthy and diseased 
ones. Around 2005, when only about 200 miRNAs 
were identified, categorization of hematological cancer 
could be done more accurately than the array analysis 
of 20,000 mRNAs[14]. miRNAs were indicated to be 
useful not only for diagnosis but also for predicting 
the outcome, as previously mentioned of let-7 in lung 
cancer[22].
   The diagnostic service for three types of cancer 
provided for medical facilities by Rosetta genomics 
in Israel. Asuragen f rom the United States 
commercialized a diagnostic kit that differentiates 
cancer and pancreatitis by measuring the expression 
levels of miRNA in a biopsy specimen of pancreas. 
Target miRNA Target Disease Developing Company
[miRNA Suppressors]
miR-122 HCV Infection Santaris Pharma A/S
miR-122 HCV Infection Regulus Therapeutics, Inc.
miR-21 Cardiac Disease, Cancer Regulus Therapeutics, Inc.
miR-208/499 Chronic Cardiac Failure miRagen Therapeutics
miR-15/195 Post-cardiac Infarct Remodeling miRagen Therapeutics
miR-206 ALS miRagen Therapeutics
miR-451 Erythrocytosis miRagen Therapeutics
[miRNA Supplement]
let-7 Lung cancer Mirna Therapeutics
miR-34 Prostate cancer Mirna Therapeutics
miR-34 Hepatic cancer Regulus Therapeutics, Inc.
miR-29 Cardiac fibrosis miRagen Therapeutics
Table 2 : Examples of Corporations Developing Nucleic Acid Drugs Targeting miRNAs
Prepared by the STFC
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Figure 6 Disappearance of Metastatic Foci of Prostate Cancer by miR-16 
Administration
In the mouse model of bone metastasis of prostate cancer (left), 
cancerous foci is spread through the body (a luciferase gene is injected in 
the cancerous cells to make them visible).      
When miR-16 was injected, the cancer foci disappeared (right).
By courtesy of Dr. Takahiro Ochiya (National Cancer Center)
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These preceding examples are evidence of the 
increased usefulness of miRNAs as disease markers.
   Recently, even more interesting results were 
reported. In 2008, two research groups independently 
reported that miRNAs exist stably in blood[27,28]. 
Since blood serum contains a rebonuclease (RNase) 
that breaks down RNAs, the presence of miRNA in 
the blood was unimaginable. Consequently, similar 
reports were published, and now, miRNAs in blood 
are in the spotlight as novel seeds for a biomarker 
development with little invasion. 
   Tewari et al at Fred Hutchinson Cancer Research 
Center found two miRNAs derived from cancerous 
cells by comparing serum miRNAs of healthy mice 
and mice transplanted with human prostate cancer 
cells. They also reported that miR-141 was useful 
as an early-detection marker for prostate cancer. 
In addition, a group from University of Texas MD 
Anderson Cancer Center has identifi ed miRNAs in the 
blood that can be a biomarker for pancreatic cancer. 
Since biopsy tests are invasive, less invasive tests 
are favorable for early-detection of cancer. Kuroda 
et al from Tokyo Medical University discovered that 
miR-92a decreased significantly in patients with 
lymphoma[29]. Furthermore they verifi ed that miR-29a 
was a great biomarker for therapeutic monitoring of 
lymphoma.
   As in the cases described above, more research 
fi ndings related to  a bio-marker of miRNAs will be 
published in near future.
4-3 A new challenge derived from the discovery of 
serum miRNAs
   The fact that miRNAs stably exist in the blood 
provided a new question of how they can stay in the 
environment where RNAs cannot. 
   One year before the discovery of miRNAs in blood, 
Valadi H. et al from the University of Gothenburg 
in Sweden discovered that mRNAs and miRNAs 
were included in exosomes, visicles with 30–100nm 
diameter that are released from cells[30]. They are 
believed to be secreted into body f luid, such as 
blood. Exosomes themselves had been known since 
the 1980s as a transportation system to bring waste 
out of the cell. However, no one imagined that they 
contained miRNAs. Furthermore, Valadi H. et al 
found that exosomes derived from murine cells 
were taken up and that they synthesized murine 
protein by human cells. This suggests the existence 
of intercellular communication through exosomes. 
In other words, miRNAs that circulates in blood is 
predicted to be taken up by another cell and function 
there. There is a high possibility that blood miRNAs 
are not only a simple biomarker but that they have 
a biological function; and therefore, research on 
intercellular communications via circulating miRNAs 
will be important in the future. 
   Secreted miRNAs are present outside of blood as 
well. They are also present in other body fl uids such 
as urine, saliva and breast milk (Figure 7). Some of 
them are believed to be useful for diagnosis, and the 
research has already started. 
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200–300 types of miRNAs were found in the exosome in blood, saliva and 
urine. 
Figure 7 : Potential Diagnostic Marker miRNAs in Body Fluid
By courtesy of Dr. Takahiro Ochiya (National Cancer Center)
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   In addition, the movement to use aforementioned 
exosomes themselves as diagnostic drugs is becoming 
active in venture companies in Europe and the United 
States. For example, Exosome Diagnostics Inc. of 
an American-German joint capital already raised 
20 million dollars by May 2010 and is on its way to 
starting business in body fluid diagnosis.
Conclusion
   Ever since the discovery of the RNAi system 
preserved in the body, the research in this field has 
been rapidly advancing mainly in the West. Although 
the development of siRNA drugs are ahead in the 
development of nucleic acid drugs expected to be the 
next generation drug after antibody drugs, the focus 
of the target is shifting to miRNA drugs. One of the 
reasons is the biological property that one miRNA 
targets multiple genes. 
   “One drug, one protein”- one antibody drug targets 
one protein. This strategy sometimes shows strong 
curative effects. However, there have been many cases 
where the effect had been less than expected or had 
caused serious side effects during development. Since 
a one-to-one relationship between antisense RNA and 
target gene underlies the siRNA drugs, it is similar to 
antibody drugs in that sense.
   On the other hand, miRNA is endogenous molecule 
and is fine tuning the multiple gene expression in 
the cells. Since a disease is caused by the disruption 
of regulatory network of multiple gene/protein 
expression, miRNA-targeting therapy is expected to 
improve the ‘network', not one gene expression.
   Another reason that miRNA drug development is 
active is the fact that it is synthesizable without special 
know-hows for development, unlike antibody drugs, 
providing opportunities for many pharmaceutical 
companies. 
   In Japan, the Japanese Association for RNAi 
Interference was founded in 2008. This association 
is not only a place for people in academia but is also 
an all-Japan consortium-like place for researchers 
and engineers from pharmaceutical as well as 
technological companies to come together to innovate 
RNAi-related technology in Japan. There are still 
many challenges, such as the stability and retention of 
synthetic miRNAs in the body, DDS development, as 
well as problems with how to handle the intellectual 
property, so the association is expected to make 
progress on them. In addition, people outside of the 
industry should also pay attention to the research 
trends of miRNAs, which have high expectations for 
the future in nucleic acid drug development.
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